Investors & Media

Investors & Media

About Immatics

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. 

 

Stock Quote

Immatics N.V.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press & Media

Immatics Appoints Biotech Executive Eliot Forster to Board of Directors

read more

Immatics beruft Biotech-Experten Eliot Forster in den Aufsichtsrat

read more

Immatics Provides Update on IMA204 ACTengine® Cell Therapy Program Targeting the Tumor Microenvironment

read more